Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
CARB-X, a public–private partnership aimed at bolstering the antibiotic pipeline, funded a diverse set of 17 early-stage drug development projects in its first year.
Nora Volkow, director of the National Institute on Drug Abuse (NIDA), discusses her ambitious aim of halving the time needed to develop non-opioid analgesics and anti-addiction drugs.
The sharing of legacy preclinical safety data among pharmaceutical companies and its integration with other information sources offers unprecedented opportunities to improve the early assessment of drug safety. Here, we discuss the experience of the eTOX project, which was established through the Innovative Medicines Initiative to explore this possibility.
The FDA could soon approve the first bispecific antibody for a non-oncology indication, but clinical applications that make full use of the biological opportunity afforded by the nascent modality remain rare.